Trial Profile
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary) ; Erlotinib; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors FibroGen
- 25 Jan 2020 Results evaluating the effect of pamrevlumab on the Prognostic value, presented at the 2020 Gastrointestinal Cancers Symposium
- 03 Feb 2017 According to a FibroGen media release, results from this study were published in the Journal of Cancer Clinical Trials.
- 03 Feb 2017 Results published in the FibroGen Media Release